Evolus’ (EOLS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a $27.00 price target on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2024 earnings at $0.00 EPS, Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.87 EPS, FY2027 earnings at $1.63 EPS, FY2028 earnings at $2.89 EPS and FY2029 earnings at $4.43 EPS.

Separately, Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Tuesday.

Evolus Price Performance

EOLS opened at $14.23 on Wednesday. The firm has a 50-day moving average price of $11.79 and a 200-day moving average price of $13.77. Evolus has a twelve month low of $9.25 and a twelve month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The company has a market capitalization of $901.04 million, a price-to-earnings ratio of -15.64 and a beta of 1.32.

Hedge Funds Weigh In On Evolus

A number of large investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in Evolus in the 4th quarter worth approximately $49,000. Quarry LP purchased a new stake in shares of Evolus in the second quarter worth $54,000. Profund Advisors LLC bought a new stake in Evolus during the second quarter valued at $130,000. Point72 Asset Management L.P. purchased a new position in Evolus during the third quarter worth about $132,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after acquiring an additional 1,291 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.